Navigation Links
BioComp Pharma Launches First Generic Drug for Tindamax(R)
Date:2/3/2009

SAN ANTONIO, Feb. 3 /PRNewswire/ -- BioComp Pharma, Inc. launched Tinidazole 500, the first generic version of the FDA-approved drug Tindamax(R). Tindamax(R) is the only oral antimicrobial drug approved by the FDA for the treatment of both trichomoniasis (trich) and bacterial vaginosis (BV). BioComp Pharma will begin shipping the generic version of Tindamax(R) in February 2009.

Generic drugs have the same active ingredients and efficacy as branded drugs but, on average, cost 30 to 80 percent less.(1) In 2007, the average price of a generic prescription drug was $34.34, while the average price of a brand-name prescription drug was $119.41, according to the National Association of Chain Drug Stores.(2)

With an estimated 7.4 million new cases of trich in men and women each year,(3) it is the most common curable sexually transmitted disease in young, sexually-active women in the United States.(4) BV affects almost one-third of women (29.2 percent) in the United States(5) and is the most common vaginal infection in women of childbearing age.(6)

Tindamax(R) is administered in one gram (two 500 mg tablets, once daily for five days) or two grams (four 500 mg tablets, once daily for two days) for the treatment of BV, compared to the twice daily, seven day oral dosing of metronidazole, the current standard of care. Tindamax(R) is administered as two grams (four 500 mg tablets for one day) for the treatment of trich. The drug's formulation helps minimize treatment time by allowing for targeted dosing and a shorter course of therapy.

About BioComp Pharma, Inc.

BioComp Pharma, Inc. is a wholly-owned subsidiary of Mission Pharmacal Company, a privately-held pharmaceutical company based in San Antonio, Texas. Established in 2008, BioComp Pharma, Inc. distributes biocomparable drug products, which are less expensive than their prescription equivalent products. For more information on BioComp Pharma, visit www.biocomppharma.com.

About Tindamax(R)

Tindamax(R) is a second-generation 5-nitroimidazole compound and is indicated in the United States for the treatment of bacterial vaginosis, trichomoniasis, the intestinal infections giardiasis and intestinal amebiasis and amebic liver abscess.

    Media Contact:
    Cohn & Wolfe
    Ms. Ami Shah
    (212) 537-8048
    ami.shah@cohnwolfe.com

(1) Saving Money on Prescription Drugs. U.S. Food and Drug Administration. Accessed at:http://www.fda.gov/fdac/features/2005/505_save.html#generic. Last accessed: January 25, 2009

(2) Industry facts-at-a-glance. National Association of Chain Drug Stores. Accessed at: http://www.nacds.org/wmspage.cfm?parm1=507. Last accessed: January 25, 2009.

(3) Trichomoniasis - CDC Fact Sheet. Centers for Disease Control. Accessed at: http://www.cdc.gov/STD/Trichomonas/STDFact-Trichomoniasis.htm. Last accessed: January 24, 2009.

(4) Trichomoniasis - CDC Fact Sheet. Centers for Disease Control. Accessed at: http://www.cdc.gov/STD/Trichomonas/STDFact-Trichomoniasis.htm. Last accessed: January 24, 2009.

(5) J.E. Allsworth, J.F. Peipert. "Prevalence of Bacterial Vaginosis: 2001-2004 National Health and Nutrition Examination Survey Data," Obstetrics and Gynecology 2007; 109(1): 114-120.

(6) Bacterial Vaginosis - CDC Fact Sheet. Centers for Disease Control. Accessed at: http://www.cdc.gov/STD/BV/STDFact-Bacterial-Vaginosis.htm . Last accessed: 2009.


'/>"/>
SOURCE BioComp Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Osteotechs Plexur M(TM) Biocomposite Receives FDA Clearance in Spine
2. Osteotech Receives FDA Clearance for Plexur M(TM) Biocomposite
3. PharmaNet Development Group Agrees to be Acquired by JLL Partners
4. Chronic Lung Disease - Axentis Pharma Attracts Investment Interest
5. Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
6. Quest PharmaTech Announces a Review of Strategic Alternatives to Enhance Shareholder Value
7. Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices
8. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
9. Sinobiopharma Reports Financial Highlights for Six-Month Period Ending November 30, 2008
10. SAFC Pharma Augments Assay Development Capabilities
11. Endo Pharmaceuticals to Announce Fourth Quarter and 2008 Full-Year Financial Results on February 27, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... UAS ... the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The company, ... proud to add Target to its list of well-respected retailers. This list includes ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
Breaking Biology News(10 mins):